Accretive vs Dilutive: How M&A Deals Impact EPS Math
When a public buyer announces a deal, the first question every sell-side analyst, portfolio manager, and CFO asks is simple: accretive vs dilutive. The label tells you in one word whether the transaction lifts pro forma earnings per share above the buyer’s standalone EPS (accretive) or pushes pro forma EPS below standalone EPS (dilutive). That single answer drives the day-one stock reaction, sets the tone for the analyst day Q&A, and gives the CFO the talking point that either earns a green session or invites a downgrade. The math is not opinion. It is a four-line bridge built from purchase price, financing mix, after-tax cost of capital, target net income, and the resulting share count, and every assumption in the bridge has to tie back to a source document.
This guide walks the full accretion/dilution model line by line, shows you the cash, stock, and mixed-deal mechanics with worked dollar examples, covers the synergy assumptions that turn a dilutive headline into an accretive year-two story, and pulls in the technical accounting (ASC 805 purchase accounting, ASC 260 EPS, ASC 350 goodwill, ASC 740 deferred tax) that institutional buyers will pressure-test on the first earnings call after close. Every figure cites a primary source. Use the section index below to jump to the part you need.
Accretive vs Dilutive: Quick Reference Table
Before you build the model, lock in the vocabulary. The table below covers the eight terms that show up on every accretion/dilution slide in an investment banking pitch book.
| Term | Definition | Sign | Where it shows up |
|---|---|---|---|
| Accretive | Pro forma EPS > standalone buyer EPS | Positive % | Press release headline, deal slide page 1 |
| Dilutive | Pro forma EPS < standalone buyer EPS | Negative % | Often relegated to footnote, paired with “year 2 accretive” |
| Neutral | Pro forma EPS = standalone within 0.5% | ~0% | Stock-for-stock mergers of equals |
| Cash EPS accretion | Accretion excluding non-cash amortization of intangibles | Usually higher than GAAP EPS accretion | Pharma, software roll-ups |
| GAAP EPS accretion | Accretion using as-reported net income | The number the SEC sees | 10-K, 10-Q, Reg G reconciliation |
| Break-even synergies | Pre-tax cost synergies required to bring accretion to zero | Dollar figure | Sensitivity tables, page 3 of the deal deck |
| Crossover year | Year pro forma EPS turns from dilutive to accretive | Year 1, 2, or 3 | Investor day waterfall |
| Earn-back period | Time to recover tangible book value dilution (banks) | Years | Bank M&A only, per FDIC merger filings |
FASB’s Accounting Standards Codification Topic 260 (Earnings Per Share) defines basic and diluted EPS and governs the share count used in every accretion calculation. The official text is at the FASB ASC 260 table of contents. Purchase price allocation rules sit in ASC 805, Business Combinations. Together these two standards control 90% of what moves your accretion number.
The Four-Line Accretion/Dilution Bridge
Every accretion/dilution model, whether built by a first-year analyst at Goldman or by a strategic finance lead at a corporate development desk, reduces to four lines:
- Pro forma net income = buyer net income + target net income + after-tax synergies – after-tax incremental interest expense – after-tax amortization of intangibles created in purchase accounting
- Pro forma diluted share count = buyer diluted shares + new shares issued to fund the deal (zero if 100% cash)
- Pro forma EPS = line 1 divided by line 2
- Accretion/(dilution) = (pro forma EPS – standalone buyer EPS) / standalone buyer EPS
If line 4 is positive, the deal is accretive. Negative, dilutive. Within +/- 0.5%, the banks will call it neutral. The walkthrough in Mergers & Inquisitions’ accretion/dilution primer mirrors this exact structure, and the more advanced version covering pre-tax interest synergies, transaction costs, and step-up depreciation is documented at Wall Street Oasis’ WSO Finance Dictionary.
Want to see how this slots into the buy-side career path? The role profile in our M&A advisor guide walks through how junior bankers actually build the deck the model feeds into, and the sell-side analyst primer covers how research desks pressure-test management’s accretion claim.
Cash-Funded Deal: When 100% Cash Is Almost Always Accretive
The cleanest accretion case is a buyer with cash on the balance sheet purchasing a profitable target. There are no new shares, so the denominator stays flat. The only earnings drag is foregone interest income on the cash you spent.
Walk through a worked example. Assume Buyer Inc. has $4.00 standalone EPS, 100 million diluted shares, $400 million standalone net income, and $1 billion of cash earning 4.5% pretax (current 3-month T-bill yield per the U.S. Treasury daily yield curve as of June 2026). The buyer pays $1 billion all-cash for Target Co., which generates $60 million of net income. Buyer’s effective tax rate is 25% (statutory federal rate 21% per 26 U.S.C. § 11 plus blended state).
| Line | Calculation | Amount |
|---|---|---|
| Buyer standalone net income | Given | $400.0M |
| (+) Target net income | Given | $60.0M |
| (-) After-tax foregone interest income | $1.0B x 4.5% x (1 – 25%) | ($33.8M) |
| (-) After-tax intangible amortization | $300M intangibles / 10 yr x (1 – 25%) | ($22.5M) |
| Pro forma net income | Sum | $403.7M |
| Diluted shares | No new shares | 100.0M |
| Pro forma EPS | $403.7M / 100.0M | $4.04 |
| Standalone EPS | Given | $4.00 |
| Accretion | ($4.04 – $4.00) / $4.00 | +0.9% |
The deal is +0.9% accretive on GAAP basis in year 1. On a cash EPS basis (adding back the $22.5M after-tax amortization), accretion jumps to +6.5%. That is why pharmaceutical buyers like Pfizer and Bristol-Myers Squibb always lead with cash EPS in deal slides, where intangible amortization can run 30%+ of pre-deal earnings. The SEC’s Regulation G, codified at 17 CFR § 244.100, requires GAAP reconciliation for any non-GAAP measure in a public filing.
Debt-Funded Deal: The Interest Expense Drag
Most large cash deals use debt, not balance sheet cash. The model changes in one line: after-tax foregone interest income becomes after-tax incremental interest expense on the new debt.
Same Buyer Inc., same target, but now Buyer issues $1 billion of 10-year senior unsecured notes at 6.5% (in line with the BBB industrial median per the Federal Reserve H.15 statistical release as of June 2026).
| Line | Calculation | Amount |
|---|---|---|
| Buyer standalone net income | Given | $400.0M |
| (+) Target net income | Given | $60.0M |
| (-) After-tax incremental interest | $1.0B x 6.5% x (1 – 25%) | ($48.8M) |
| (-) After-tax intangible amortization | $300M / 10 yr x (1 – 25%) | ($22.5M) |
| Pro forma net income | Sum | $388.7M |
| Diluted shares | No new shares | 100.0M |
| Pro forma EPS | $388.7M / 100.0M | $3.89 |
| Accretion/(dilution) | ($3.89 – $4.00) / $4.00 | (2.8%) |
Debt-funded the same deal goes from +0.9% accretive to -2.8% dilutive purely because of the spread between the 4.5% T-bill yield and the 6.5% borrowing cost. The accretion test is brutally sensitive to the cost of debt. Tax deductibility of interest is capped at 30% of adjusted taxable income under 26 U.S.C. § 163(j), which can push the after-tax interest drag higher for highly levered buyers. The 2024 final regulations are at 26 CFR § 1.163(j)-1.
Two practical wrinkles change the picture. First, the deal team will usually model a blended cost of debt that mixes a senior secured term loan (priced off SOFR + 200 to 350 bps for investment-grade names per Federal Reserve H.15) with a senior unsecured bond tranche. The blend is almost always 100-150 bps below the unsecured-only number. Second, large deals often include a bridge loan commitment that gets refinanced into permanent debt within 6 to 12 months. Commitment fees on the bridge (typically 15 to 30 bps annualized per the Loan Syndications and Trading Association standard credit agreement form) are technically transaction costs but are sometimes baked into the financing assumption. If the buyer’s existing debt has change-of-control puts, the model also has to refinance that stack at current market rates, which can flip an accretive deal dilutive on the financing line alone.
Stock-Funded Deal: When the Denominator Wins or Loses
An all-stock deal flips the analysis. There is no new interest expense and no foregone interest income. The denominator does all the work. The single test is the P/E ratio comparison: if the buyer’s P/E is higher than the target’s effective P/E (purchase price divided by target net income), the deal is accretive. If the buyer’s P/E is lower, it is dilutive.
Buyer Inc. trades at $80 (20x P/E on $4.00 EPS). Buyer pays $1 billion in stock for Target Co. (16.7x P/E on $60M net income). Buyer must issue $1B / $80 = 12.5 million new shares.
| Line | Calculation | Amount |
|---|---|---|
| Buyer standalone net income | Given | $400.0M |
| (+) Target net income | Given | $60.0M |
| (-) After-tax intangible amortization | $300M / 10 yr x (1 – 25%) | ($22.5M) |
| Pro forma net income | Sum | $437.5M |
| Diluted shares | 100M + 12.5M | 112.5M |
| Pro forma EPS | $437.5M / 112.5M | $3.89 |
| Accretion/(dilution) | ($3.89 – $4.00) / $4.00 | (2.8%) |
Dilutive 2.8%, exactly mirroring the debt-funded outcome by coincidence of inputs. The lesson is mechanical: at 16.7x target P/E, the buyer’s 20x P/E earns only a 5%-yield (1 / 20) on the new shares versus the 6%-yield (1 / 16.7) the target earnings produce, but the after-tax amortization drag tips the deal into negative territory. Wachtell, Lipton, Rosen & Katz’s deal commentary at M&A Outlook 2025 walks through the P/E arithmetic with current-cycle examples.
Mixed-Consideration Deal: 50/50 Cash and Stock
Real-world large-cap deals are rarely all cash or all stock. The 2022 Microsoft-Activision deal was all cash ($75.4 billion per the Microsoft 8-K dated January 18, 2022). The 2022 Amgen-Horizon Therapeutics deal was all cash ($28.3 billion per the Amgen 8-K dated December 12, 2022). But many billion-dollar deals split the consideration. The 2023 Pfizer-Seagen deal was all cash ($43 billion per the Pfizer 8-K dated March 12, 2023), while Capital One’s 2024 announcement to buy Discover was all stock ($35.3 billion per the Capital One 8-K dated February 19, 2024).
For a 50/50 mixed deal on the same Buyer/Target setup ($500M cash funded by debt at 6.5%, $500M stock at $80/share = 6.25M new shares):
| Line | Calculation | Amount |
|---|---|---|
| Buyer + Target net income | $400M + $60M | $460.0M |
| (-) After-tax incremental interest | $500M x 6.5% x (1 – 25%) | ($24.4M) |
| (-) After-tax intangible amortization | $300M / 10 yr x (1 – 25%) | ($22.5M) |
| Pro forma net income | Sum | $413.1M |
| Diluted shares | 100M + 6.25M | 106.25M |
| Pro forma EPS | $413.1M / 106.25M | $3.89 |
| Accretion/(dilution) | ($3.89 – $4.00) / $4.00 | (2.8%) |
The mixed deal lands at exactly the same dilution as the pure debt or pure stock case in our example because the inputs are calibrated. In live deal work, the buyer rarely splits the consideration cleanly. Capital structure choices reflect tax (interest deductibility under IRC 163(j)), credit rating (Moody’s and S&P downgrade thresholds), and target shareholder preference (Section 368(a) reorganization treatment requires at least 40% stock per 26 U.S.C. § 368). The Skadden M&A deal book guide at 2024 M&A Review covers tax-free reorganization mechanics in detail.
Synergies: The Lever That Turns Dilutive Into Accretive
Synergies do most of the heavy lifting in the published accretion narrative. Cost synergies (headcount reduction, facility consolidation, procurement) flow to pretax operating income and become accretion fuel after tax. Revenue synergies (cross-sell, pricing) are softer and rarely credited by buy-side analysts in year-1 model runs.
Continue the debt-funded Buyer/Target example. The deal is -2.8% dilutive year 1. Management announces $50 million of run-rate cost synergies, fully phased by end of year 2, with $20 million realized in year 1.
| Year | Realized synergies (pre-tax) | After-tax synergies (25%) | Pro forma net income | Pro forma EPS | Accretion vs $4.00 |
|---|---|---|---|---|---|
| Year 1 | $20M | $15M | $403.7M | $4.04 | +0.9% |
| Year 2 | $50M | $37.5M | $426.2M | $4.26 | +6.5% |
| Year 3 | $50M | $37.5M | $426.2M | $4.26 | +6.5% |
The same -2.8% dilutive deal becomes +0.9% accretive year 1 and +6.5% accretive year 2 once synergies are loaded in. This is the crossover year math that bankers walk investors through on day 1 of the deal announcement. Bain & Company’s annual M&A report at Global M&A Report 2025 finds that strategic acquirers actually realize only 60-80% of announced cost synergies on average, with the gap widening for cross-border and cross-industry deals. McKinsey’s research at The flip side of large M&A deals reaches similar conclusions on the synergy realization rate.
Cost synergies fall into three buckets that have very different realization rates. Headcount synergies (eliminating overlap in finance, HR, IT, legal, and corporate functions) are the highest-confidence bucket, with Boston Consulting Group analysis at BCG M&A practice insights showing realization in the 80-95% range when one-time severance costs are properly funded. Facility and real estate consolidation (closing duplicate offices, warehouses, plants) is the second bucket and typically lands in the 60-75% range because lease-exit costs and asset write-downs are larger than initial estimates. Procurement and supplier-pricing synergies (vendor consolidation, volume discounts) are the softest bucket and frequently disappoint, with Deloitte M&A integration data at Deloitte M&A insights showing realization below 50% in roughly one-third of deals. Revenue synergies are the softest of the soft. PwC’s integration benchmarking at PwC Deals finds that publicly announced revenue synergies are realized at less than 40% within 24 months of close. Smart accretion models discount revenue synergies by 50-60% at the model-build stage, then let the deal team add them back if they want to defend a stretched headline number.
Goodwill, Intangibles, and the ASC 805 Amortization Drag
Purchase accounting under ASC 805 requires the buyer to allocate the purchase price to identifiable assets and liabilities at fair value. Anything left over becomes goodwill. Identifiable intangibles (customer relationships, developed technology, trade names, in-process R&D) are amortized over their useful lives. Goodwill is not amortized for GAAP reporting but is tested annually for impairment under ASC 350.
The $300 million intangibles assumption in our running example translates to $30 million pre-tax amortization per year. At a 25% tax rate, that is $22.5 million of after-tax earnings drag every year for 10 years. On a $400 million standalone earnings base, that is a 5.6% annual hit to GAAP earnings. Cash flow is unaffected, which is why dealmakers and credit analysts emphasize cash EPS for amortization-heavy deals. The AICPA’s accounting and valuation guide on intangible asset valuation at Assets Acquired to Be Used in R&D Activities is the standard reference. PwC’s guide to business combinations under ASC 805 at Business Combinations and Noncontrolling Interests covers the mechanics step by step.
Pharmaceutical and life sciences buyers carry the largest intangible amortization loads. Bristol-Myers Squibb reported $9.4 billion of intangible amortization in 2024 per the BMS 10-K filings on EDGAR, which is why management consistently reports both GAAP and non-GAAP “cash” EPS in earnings releases. The non-GAAP measure has been the subject of SEC comment letters for years, with the staff’s positions summarized in SEC Compliance and Disclosure Interpretations on Non-GAAP Financial Measures.
Step-Up Depreciation and Deferred Tax Considerations
Beyond intangibles, purchase accounting can mark up tangible assets (PP&E) to fair value. In a taxable asset acquisition or a Section 338(h)(10) election, the buyer also gets a tax basis step-up, generating future tax shields. In a stock acquisition without a 338(h)(10), there is no tax basis step-up, which creates a deferred tax liability for the GAAP book-tax difference under ASC 740.
The 338(h)(10) election is governed by 26 U.S.C. § 338 and the implementing regulations at 26 CFR § 1.338(h)(10)-1. The election treats a stock sale as if it were an asset sale for tax purposes, generating step-up depreciation that flows through the income statement as additional tax shields. The trade-off: the seller pays ordinary tax on any depreciation recapture, so deal lawyers usually negotiate a gross-up payment from buyer to seller equal to the seller’s incremental tax cost. The Tax Adviser’s coverage at Sec. 338(h)(10) Election Considerations walks through the mechanics.
If you are on the sell side and weighing how this tax architecture affects your final proceeds, our stock purchase agreement guide covers the deal-doc language, and the breakdown in installment sale vs cash sale compares the tax outcomes at the seller level.
Transaction Costs, Financing Fees, and the Day-One Hit
Transaction costs include advisor fees, legal fees, due diligence costs, financing arrangement fees, and Hart-Scott-Rodino premerger notification filing fees ($30,000 to $2.5 million depending on deal size per the FTC HSR fee schedule). Under ASC 805, transaction costs are expensed as incurred, not capitalized into goodwill. That creates a one-time hit to net income in the closing year.
A $1 billion deal might carry $40-60 million of transaction costs (banker fees alone at 1-2% per the DEFM14A merger proxy filings on EDGAR show typical Goldman/Morgan Stanley/JPM advisory fees of 0.5-1.0% on $1B+ deals). Financing fees for the debt are capitalized as debt issuance costs and amortized over the term of the debt under ASC 835-30. The accretion model should flag the closing-year transaction cost as a special item, since most sell-side analysts will exclude it from the recurring accretion line but will hit the company on the full GAAP number in the actual 10-K. Houlihan Lokey’s M&A market update at Houlihan Lokey Insights publishes quarterly fee benchmarks for mid-cap deals.
The fee components break down further. Legal fees for the buyer and target combined typically run $15-25 million on a $1 billion deal (Wachtell, Skadden, Cravath, and Sullivan & Cromwell are the historical top-fee firms per The American Lawyer deal-fee surveys). Accounting and tax due diligence by Big Four firms adds $3-8 million. Antitrust counsel, regulatory filings beyond HSR, and environmental and IP diligence add another $2-5 million combined. Insurance (representations and warranties policies are now standard on deals above $100 million per the Aon Transaction Solutions annual report) adds 2-4% of policy limits as one-time premium. Lining up these costs in a separate transaction-cost schedule is the discipline that distinguishes a bulletproof model from a back-of-envelope estimate.
Break-Even Synergies: The Sensitivity Table Every Banker Builds
The break-even synergy figure is the pretax cost synergy required to bring accretion to zero. It is the single most useful sensitivity output because it tells the board, the rating agency, and the buy-side what the deal needs to deliver before any value is created for the buyer’s shareholders. For our debt-funded -2.8% dilutive deal:
| Required pro forma net income to break even | $400.0M |
|---|---|
| Actual pro forma net income (no synergies) | $388.7M |
| Gap | $11.3M after-tax |
| Required pre-tax synergies (at 25% tax) | $15.1M |
| Implied % of target operating expenses | Depends on target cost base |
If target operating expenses are $400 million, $15.1 million pretax break-even synergies are 3.8% of the cost base, which is achievable in most overlap deals. If target operating expenses are $80 million, the same $15.1 million is 19% of the cost base, which strains credibility. The Houlihan Lokey M&A market commentary and the quarterly Refinitiv league tables at LSEG Deals Intelligence publish the typical synergy disclosures for closed deals each quarter.
Bank M&A: Tangible Book Value Earn-Back as the Real Test
For bank acquisitions, accretion/dilution analysis runs in parallel with tangible book value (TBV) earn-back analysis. Bank investors and regulators care about TBV dilution because tangible common equity drives regulatory capital ratios under the Federal Reserve’s Basel III capital framework. The crossover method (favored since the 2017 PNC-BBVA USA deal commentary by Keefe, Bruyette & Woods) compares the cumulative pro forma EPS uplift over time against the closing-day TBV dilution. The earn-back period is the year cumulative EPS accretion equals the per-share TBV dilution.
Capital One’s $35.3 billion all-stock acquisition of Discover Financial (announced February 2024 per the Capital One 8-K) disclosed roughly 7% EPS accretion year 1 with a TBV earn-back of under 3 years on a crossover basis. The deal closed in 2025 and is the largest U.S. bank deal since the 2008 financial crisis. The Office of the Comptroller of the Currency conditional approval document at OCC Interpretations and Actions covers the regulatory conditions.
The FDIC’s bank merger application data at FDIC Bank Merger Information documents 2024-2025 trends. For deal docs and tax-side analysis of structure-driven outcomes, see our golden parachute 280G guide, which covers the executive-comp tax piece that frequently surfaces in bank deals.
Sell-Side Analyst Pressure Test: What Buy-Siders Ask
The minute a deal is announced, sell-side analysts at firms like JPMorgan, Bank of America, Morgan Stanley, Goldman Sachs, and Evercore ISI publish notes within hours. The questions on the first investor call follow a predictable script:
- What is the GAAP accretion, not just cash EPS accretion? Buy-siders haircut cash EPS adjustments at 50-100%.
- What is the break-even synergy figure? If it requires more than 5% of target opex, expect skepticism.
- What is the synergy phase-in by year? Year 1 synergies above 40% of run-rate are aggressive per Bain’s M&A research.
- What is the year of full crossover to accretion? Anything beyond year 3 invites doubt.
- Has the deal accounted for transaction costs and step-up depreciation reversals correctly?
- What is the pro forma debt-to-EBITDA ratio at close and 12-months out? Rating agency thresholds matter.
- Does the EPS guidance reflect the deal or just standalone?
The Morgan Stanley M&A insights page at Morgan Stanley Ideas: M&A publishes deal-by-deal commentary on these questions for major transactions. Goldman Sachs publishes similar commentary at Goldman Sachs Mergers and Acquisitions Insights. If you are early in a buy-side career and want to understand how analysts model these questions, our private equity analyst career guide walks through the model build.
Real Deal Examples: Accretive Wins and Dilutive Misses
The case studies below illustrate the accretive/dilutive label in action.
| Deal | Year | Size | Structure | Year 1 EPS impact | Source |
|---|---|---|---|---|---|
| Microsoft-Activision | 2023 close | $75.4B | All cash | Modest dilutive year 1, accretive year 2 per management | Microsoft 8-K |
| Pfizer-Seagen | 2023 close | $43.0B | All cash, debt-funded | Slightly dilutive year 1-2, accretive year 3 per Pfizer 8-K | Pfizer 8-K March 12, 2023 |
| Amgen-Horizon Therapeutics | 2023 close | $28.3B | All cash, debt-funded | Non-GAAP accretive year 1 per Amgen 8-K | Amgen 8-K December 12, 2022 |
| Capital One-Discover | 2025 close | $35.3B | All stock | ~7% accretive year 1, TBV earn-back <3 years | COF 8-K |
| Cisco-Splunk | 2024 close | $28B | All cash | Accretive to non-GAAP EPS year 1 per Cisco 8-K | Cisco 8-K September 21, 2023 |
| Chevron-Hess | Pending 2026 | $53B | All stock | Accretive cash flow per share within 12 months per Chevron disclosure | Chevron 8-K October 23, 2023 |
What unites the accretive deals is one or more of: low buyer cost of debt, high buyer P/E relative to target P/E, sizeable cost synergies, or large standalone earnings base making the deal earnings additive without much dilution drag. What unites the dilutive deals is the inverse. Deal commentary from Davis Polk & Wardwell at Davis Polk M&A Practice tracks these patterns by sector.
Common Accretion Model Mistakes
The model is mechanical, but small errors compound. The most frequent mistakes:
- Forgetting the after-tax interest expense adjustment. Interest is deductible (subject to 163(j) limits) so the drag is interest x (1 – tax rate), not the pretax interest figure.
- Using the wrong target net income. Take the most recent LTM normalized figure, not GAAP if there are one-time charges. The Carta benchmarking data at State of Private Markets covers how private targets normalize earnings for deal purposes.
- Ignoring intangible amortization. Use a useful-life-weighted blended period. ASC 805 requires identifiable intangibles be valued separately, not all dumped into goodwill.
- Double-counting synergies as both cost and revenue. Discipline matters: cost synergies are net of any new headcount needed to capture revenue synergies.
- Forgetting the share count uses Treasury Stock Method for buyer options. ASC 260 requires the dilutive-effect calculation for in-the-money options and warrants. The mechanics are at ASC 260 Earnings Per Share.
- Mismatching deal-close date with the fiscal year boundary. A deal closing on October 1 contributes only 25% of the target’s annual earnings to year 1 pro forma results, not 100%.
- Using the wrong cost of new debt. Take live BBB/BB market rates per the Federal Reserve H.15, not the buyer’s existing weighted average cost of debt.
The accretion model walkthroughs at Mergers & Inquisitions and Wall Street Oasis show the corrected math for each of these pitfalls.
Building the Model in Excel: Step-by-Step Build Sequence
| Step | What you build | Source cell |
|---|---|---|
| 1 | Buyer standalone P&L (rev, EBIT, interest, tax, NI, EPS) | Latest 10-K / 10-Q |
| 2 | Target standalone P&L | Latest 10-K / 10-Q or CIM if private |
| 3 | Purchase price tab (offer price, premium, EV, equity value) | Reuters / FactSet comps |
| 4 | Financing tab (cash + debt + stock split, debt rate, share price) | Bond comps + live share price |
| 5 | Purchase price allocation (PPA): identifiable intangibles, goodwill, step-up DT&A, deferred tax liability | Comparable deal PPAs from EDGAR 10-K filings |
| 6 | Synergy tab: pretax cost synergies + revenue synergies by year, phase-in schedule | Management guidance + benchmark from Bain |
| 7 | Pro forma P&L: combine, layer in synergies, interest drag, amortization | Formula-driven from steps 1-6 |
| 8 | Pro forma share count: buyer shares + new issuance + treasury stock method for options | 10-K + ASC 260 |
| 9 | Output: pro forma EPS, accretion %, break-even synergies, sensitivity table on synergies and deal premium | Direct calculation |
Wall Street Prep’s accretion/dilution model walkthrough at Wall Street Prep Accretion/Dilution Guide provides a free downloadable template that follows this exact sequence. The Macabacus tutorial at Macabacus Accretion/Dilution and Merger Model covers the same build with shortcuts used at investment banks. For an industry view of how PE buyers approach related modeling work, see our LBO model from scratch guide and the worked example in paper LBO walkthrough.
Accretion vs Value Creation: The Trap of Optical Accretion
An accretive deal is not automatically a value-creating deal. The classic Warren Buffett critique (laid out in his Berkshire Hathaway shareholder letters) is that any buyer with a high P/E can manufacture accretive EPS simply by acquiring a target with a lower P/E, regardless of strategic fit. The accretion is real on a GAAP basis but destroys long-run shareholder value if the acquired earnings have lower growth, lower margins, or higher capital intensity than the buyer’s existing business.
Real value creation requires return on invested capital (ROIC) on the deal greater than the buyer’s cost of capital. The McKinsey research at The flip side of large M&A deals and the long-running Booz/Strategy& analysis at Strategy& Insights consistently find that 50-70% of large deals destroy shareholder value over 3-5 years despite being accretive in year 1. Hess Corporation and Activision both delivered accretive headlines; both buyers’ stocks then traded sideways or down for 12+ months post-close because the market priced in execution risk above the EPS bump.
The discipline buy-side analysts use to separate optical accretion from real value creation is to layer the accretion model against a DCF that values the synergies separately. The DCF answers “is the buyer paying less than the present value of the synergies plus the standalone target value?” If yes, the deal creates value. If no, the EPS accretion is just rearranging the income statement deck chairs. Build the DCF using the playbook in our discounted cash flow business valuation guide and the worked walk-through in DCF valuation business sale 2026. For the underlying valuation math, see business valuation formula methods and math and how to determine the value of a business.
TLDR and Key Takeaways
- Accretive vs dilutive is one metric: pro forma EPS relative to standalone buyer EPS. Pro forma higher means accretive. Lower means dilutive.
- Cash deals with idle balance-sheet cash are almost always accretive. Debt-funded cash deals depend on whether after-tax target earnings exceed the after-tax interest cost.
- Stock deals follow the P/E rule. Buyer P/E higher than target effective P/E equals accretive. Buyer P/E lower equals dilutive.
- Synergies turn dilutive year-1 deals into accretive year-2 or year-3 stories. Bain finds only 60-80% of announced synergies are realized.
- Intangible amortization under ASC 805 drags GAAP EPS for 5-15 years. Cash EPS adds it back; SEC Reg G requires GAAP reconciliation.
- Bank deals use TBV earn-back, not pure accretion. The crossover method ties the two together.
- Break-even synergies tell you how plausible the deal actually is. Anything above 5% of target opex invites skepticism.
- Accretion is not the same as value creation. A high-P/E buyer can manufacture accretion by buying a low-P/E target without creating long-run value.
- Build the model in 9 steps. Start with the two standalone P&Ls and end with the sensitivity table. Pull every cost-of-debt and tax-rate input from primary sources (Treasury, Federal Reserve H.15, IRC).
- Pressure-test against a DCF. Accretion plus DCF positive equals real value creation. Accretion alone equals optical accretion.
Anyone who can build the 4-line accretion bridge from a blank Excel tab and source every input from a primary document is ready for the first round of any IB / corporate development / equity research interview that touches M&A. The math itself is not hard. The discipline to source every assumption, layer purchase accounting correctly, and separate optical accretion from real value creation is what separates the deck monkeys from the analysts running the model.